Machina Capital S.A.S. acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 15,236 shares of the company's stock, valued at approximately $365,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. LPL Financial LLC increased its holdings in Kenvue by 4.9% in the 4th quarter. LPL Financial LLC now owns 2,064,405 shares of the company's stock valued at $44,075,000 after buying an additional 96,030 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Kenvue by 4.2% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,609,212 shares of the company's stock worth $76,515,000 after buying an additional 143,861 shares in the last quarter. NEOS Investment Management LLC boosted its stake in shares of Kenvue by 31.5% in the 4th quarter. NEOS Investment Management LLC now owns 103,849 shares of the company's stock valued at $2,217,000 after purchasing an additional 24,888 shares during the last quarter. Blair William & Co. IL boosted its stake in shares of Kenvue by 0.9% in the 4th quarter. Blair William & Co. IL now owns 194,250 shares of the company's stock valued at $4,147,000 after purchasing an additional 1,755 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Kenvue in the 4th quarter valued at about $521,348,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have commented on KVUE shares. JPMorgan Chase & Co. dropped their target price on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday. Bank of America lowered their target price on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, July 15th. Citigroup reduced their price objective on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a research report on Tuesday, July 15th. Barclays reduced their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Tuesday, July 15th. Finally, Redburn Atlantic began coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective for the company. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $24.79.
Read Our Latest Report on Kenvue
Kenvue Trading Down 1.6%
KVUE stock traded down $0.36 on Tuesday, reaching $22.00. The company's stock had a trading volume of 16,354,271 shares, compared to its average volume of 17,149,447. The business has a fifty day simple moving average of $21.99 and a two-hundred day simple moving average of $22.38. Kenvue Inc. has a 12-month low of $18.10 and a 12-month high of $25.17. The firm has a market cap of $42.22 billion, a PE ratio of 39.90, a PEG ratio of 3.81 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. During the same period in the prior year, the firm posted $0.28 earnings per share. The company's quarterly revenue was down 3.9% on a year-over-year basis. As a group, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More

Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.